- Home
- Publications
- Publication Search
- Publication Details
Title
Elbasvir and grazoprevir for the treatment of hepatitis C
Authors
Keywords
-
Journal
Expert Review of Anti-Infective Therapy
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2021-01-14
DOI
10.1080/14787210.2021.1874351
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhancement of thermo-mechanical stability for nanocomposites containing plasma treated carbon nanotubes with an experimental study and molecular dynamics simulations
- (2020) Hana Jung et al. Scientific Reports
- Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM
- (2020) Anders Boyd et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan
- (2020) Pin-Nan Cheng et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations
- (2020) Ming-Lung Yu et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Cure or curd: Modification of lipid profiles and cardio‐cerebrovascular events after hepatitis C virus eradication
- (2020) Chung‐Feng Huang et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection
- (2020) Amy Puenpatom et al. Infectious Diseases and Therapy
- Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
- (2020) Chung-Feng Huang et al. Clinical and Molecular Hepatology
- Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
- (2019) Nathalie Alazard-Dany et al. Viruses-Basel
- Association of Hepatitis C and B Virus Infection with CKD and Impact of Hepatitis C Treatment on CKD
- (2019) Hui Zhang et al. Scientific Reports
- Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment
- (2019) Luzelena Caro et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Transplanting hepatitis C virus–infected hearts into uninfected recipients: A single‐arm trial
- (2019) Rhondalyn C. McLean et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia
- (2019) Zobair M. Younossi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update
- (2019) Elise J. Smolders et al. CLINICAL PHARMACOKINETICS
- An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions
- (2019) Chung-Feng Huang et al. JOURNAL OF INFECTIOUS DISEASES
- Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients
- (2019) Ann E. Woolley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis
- (2019) Ira M. Jacobson et al. Clinical and Translational Gastroenterology
- Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial
- (2019) Yi-Chun Lin et al. Infection and Drug Resistance
- Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial
- (2019) Anne Boerekamps et al. Lancet Gastroenterology & Hepatology
- Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single‐centre experience
- (2019) Lennert Fransen et al. HAEMOPHILIA
- Real world experience with Grazoprevir/Elbasvir in the treatment of previously “difficult to treat” patients infected with HCV genotype 1 and 4
- (2019) Dorota Zarębska‐Michaluk et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan
- (2019) Tzu‐Cheng Tsai et al. JOURNAL OF MEDICAL VIROLOGY
- Hepatitis C
- (2019) C Wendy Spearman et al. LANCET
- Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial
- (2019) Marcelo Cypel et al. Lancet Respiratory Medicine
- Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population
- (2019) Debra T. Choi et al. ANTIVIRAL RESEARCH
- Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected Recipients
- (2018) Christine M. Durand et al. ANNALS OF INTERNAL MEDICINE
- Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial
- (2018) Graham R. Foster et al. HEPATOLOGY
- High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: Interim Results of the STREAGER Study
- (2018) A. Abergel et al. JOURNAL OF HEPATOLOGY
- Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
- (2018) Johannes Vermehren et al. JOURNAL OF HEPATOLOGY
- The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C
- (2018) Po-Cheng Liang et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study
- (2018) A. Brown et al. JOURNAL OF VIRAL HEPATITIS
- Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis
- (2018) Tarik Asselah et al. LIVER INTERNATIONAL
- Management of acute HCV infection in the era of direct-acting antiviral therapy
- (2018) Marianne Martinello et al. Nature Reviews Gastroenterology & Hepatology
- The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C
- (2018) Batbold Batsaikhan et al. Oncotarget
- Twelve-Month Outcomes After Transplant of Hepatitis C–Infected Kidneys Into Uninfected Recipients
- (2018) Peter P. Reese et al. ANNALS OF INTERNAL MEDICINE
- Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection
- (2018) Sara Yee Tartof et al. Clinical Journal of the American Society of Nephrology
- Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study
- (2018) Masanori Atsukawa et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: results from the Spanish HEPA-C real-world cohort
- (2018) M. Hernández-Conde et al. JOURNAL OF VIRAL HEPATITIS
- The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment
- (2018) Christian Qvigstad et al. MEDICINE
- Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
- (2018) Sylvia Drazilova et al. Canadian Journal of Gastroenterology and Hepatology
- Decline of Increased Risk Donor Offers on Waitlist Survival in Heart Transplantation
- (2018) Michael S. Mulvihill et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis
- (2018) Lawrence Serfaty et al. JOURNAL OF VIRAL HEPATITIS
- Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
- (2017) Paul Kwo et al. GASTROENTEROLOGY
- The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection
- (2017) Parag Mahale et al. GUT
- Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study
- (2017) Christophe Hézode et al. HEPATOLOGY
- Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study
- (2017) Tai-Shuan Lai et al. HEPATOLOGY
- Hepatitis C treatment from “response-guided” to “resource-guided” therapy in the transition era from interferon-containing to interferon-free regimens
- (2017) Ming-Lung Yu JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients
- (2017) David S. Goldberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review
- (2017) Louisa Degenhardt et al. Lancet Global Health
- Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort
- (2016) M. Elaine Eyster et al. AMERICAN JOURNAL OF HEMATOLOGY
- Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
- (2016) Gregory J. Dore et al. ANNALS OF INTERNAL MEDICINE
- The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons
- (2016) Frederick C. Lahser et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of antiviral therapy for HCV on lipid levels
- (2016) Stefan Mauss et al. ANTIVIRAL THERAPY
- Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment
- (2016) Elise J. Smolders et al. DRUG SAFETY
- Elbasvir/Grazoprevir: First Global Approval
- (2016) Gillian M. Keating DRUGS
- Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial
- (2016) Eric Lawitz et al. HEPATOLOGY
- Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study
- (2016) Tung-Hung Su et al. HEPATOLOGY
- Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection
- (2016) Chandana Papudesu et al. Hepatology International
- The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: A systematic review and meta-analysis
- (2016) Pasquale Ambrosino et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
- (2016) Hiromitsu Kumada et al. JOURNAL OF GASTROENTEROLOGY
- HCV epidemiology in high-risk groups and the risk of reinfection
- (2016) Håvard Midgard et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial
- (2016) Jan Sperl et al. JOURNAL OF HEPATOLOGY
- Recent Advances in Antiviral Therapy for Chronic Hepatitis C
- (2016) Akihiro Tamori et al. MEDIATORS OF INFLAMMATION
- Genotype specific peripheral lipid profile changes with hepatitis C therapy
- (2016) Mark R Pedersen et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Hepatitis C virus relies on lipoproteins for its life cycle
- (2016) Germana Grassi WORLD JOURNAL OF GASTROENTEROLOGY
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
- (2015) Stefan Zeuzem et al. ANNALS OF INTERNAL MEDICINE
- Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.
- (2015) Maria Buti et al. CLINICAL INFECTIOUS DISEASES
- Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection
- (2015) Adriaan J van der Meer GUT
- Chronic hepatitis C infection is associated with insulin resistance and lipid profiles
- (2015) Chia-Yen Dai et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
- (2015) Xavier Forns et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
- (2015) Mark Sulkowski et al. LANCET
- Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
- (2015) David Roth et al. LANCET
- Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
- (2015) Jürgen K Rockstroh et al. Lancet HIV
- Hepatitis C Virus Infection among Injection Drug Users with and without Human Immunodeficiency Virus Co-Infection
- (2014) Meng-Hsuan Hsieh et al. PLoS One
- Hepatitis C Virus Infection Increases Risk of Developing End-Stage Renal Disease Using Competing Risk Analysis
- (2014) Jia-Jung Lee et al. PLoS One
- Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant
- (2014) H.-H. Hsiao et al. Transplant Infectious Disease
- Hepatitis C virus NS5A inhibitors and drug resistance mutations
- (2014) Shingo Nakamoto WORLD JOURNAL OF GASTROENTEROLOGY
- Discovery of MK-8742: An HCV NS5A Inhibitor with Broad Genotype Activity
- (2013) Craig A. Coburn et al. ChemMedChem
- Computational Study on the Drug Resistance Mechanism against HCV NS3/4A Protease Inhibitors Vaniprevir and MK-5172 by the Combination Use of Molecular Dynamics Simulation, Residue Interaction Network, and Substrate Envelope Analysis
- (2013) Weiwei Xue et al. Journal of Chemical Information and Modeling
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
- (2013) Christophe Hézode et al. JOURNAL OF HEPATOLOGY
- Meta-analysis of observational studies: hepatitis C and survival after renal transplant
- (2013) F. Fabrizi et al. JOURNAL OF VIRAL HEPATITIS
- MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
- (2012) Vincenzo Summa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Treatment of acute HCV infection
- (2011) Jason Grebely et al. Nature Reviews Gastroenterology & Hepatology
- Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel
- (2011) Laurent Chatel-Chaix et al. Viruses-Basel
- Association of Hepatitis C and B Virus Infection With CKD in an Endemic Area in Taiwan: A Cross-sectional Study
- (2010) Jia-Jung Lee et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Underutilization of Hepatitis C-Positive Kidneys for Hepatitis C-Positive Recipients
- (2010) L. M. Kucirka et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Meta‐Analysis: Increased Mortality Associated with Hepatitis C in HIV‐Infected Persons Is Unrelated to HIV Disease Progression
- (2009) Ting‐Yi Chen et al. CLINICAL INFECTIOUS DISEASES
- Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study
- (2008) Chia-Yen Dai et al. JOURNAL OF HEPATOLOGY
- Acute hepatitis C
- (2008) Anurag Maheshwari et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now